Drug intelligence / Profile preview

LNK01007

Development stage: Preclinical
Lead developer: Lynk Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

LNK01007 is an oral, systemic small molecule inhibitor targeting the pseudokinase (JH2) domain of non-receptor tyrosine-protein kinase TYK2. Developed by Lynk Pharmaceuticals, LNK01007 is designed to allosterically inhibit TYK2, thereby blocking downstream JAK-STAT signaling pathways involved in autoimmune and inflammatory responses. The drug is currently in preclinical development for the treatment of inflammatory bowel disease (IBD).

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on LNK01007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNK01007.

Explore the full profile